RLIP76 contributes to pancreatic cancer cell resistance to chemotherapy and radiation

June 19, 2012

Researchers at the City of Hope Comprehensive Cancer Center have not only identified a protein that allows pancreatic cancer cells to resist therapy but also developed a way to block it, according to results presented at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference.

"Cancer of the is notoriously difficult to treat because it usually presents at late stages due to minimal or nonspecific symptoms in the early stages. Thus, surgical treatment is either not possible or fails to cure most patients, resulting in a dismal — 90 percent of patients are likely to die within a year," said Sanjay Awasthi, M.D., professor of medical oncology and therapeutics research, and diabetes, endocrinology and metabolism at City of Hope in Duarte, Calif.

One of the reasons that pancreatic cancer is so difficult to treat is that the tumor cells are largely resistant to the cell death caused by radiation and chemotherapy. Awasthi and colleagues have previously shown that the RLIP76 plays a key role in defending cells from other types of cancers from death caused by exposure to chemotherapy or radiation.

"RLIP76 works like an exhaust system," said Awasthi. "It pumps out the toxic chemicals that accumulate in the cancer cell as a result of chemo- or radiotherapy before they can cause cell death."

Now, Awasthi and colleagues have found that there is more RLIP76 in human pancreatic cancer cells than there is in normal human pancreatic cells. Depleting levels of RLIP76 killed human pancreatic in culture and shrank established human pancreatic tumors in mice. Moreover, blocking RLIP76 or depleting levels of the protein dramatically enhanced the ability of radiation and the chemotherapeutic agent doxorubicin to destroy human pancreatic cells in culture.

"Pancreatic cancer patients are a special case of the particularly unlucky, and in many ways the most miserable. The drug and radiation resistance of this cancer is legendary," Awasthi said.

"Because we have defined RLIP76 as an essential drug- and radiation-resistance mediating protein, and because blockade of RLIP76 caused regression of less therapy-resistant cancers (lung, colon, breast), as well as equally resistant cancers (kidney, prostate, resistant neuroblastoma), we undertook the present studies to determine whether this treatment could be effective in pancreatic cancer.

"Fortunately, our data show that the seemingly unconquerable pancreatic cancer has an Achilles heel; its toxin exhaust system," he explained. "Moreover, plugging this exhaust caused cell death, leaving normal relatively unfazed. We hope to translate these studies into clinical trials in the near future."

According to Awasthi, they saw an added benefit to depleting levels of RLIP76 in the mice with established tumors: a decrease in blood sugar, cholesterol and triglycerides. "These findings indicate that it might be possible to develop a single class of medications that have potent antidiabetic and anticancer effects," he said.

Awasthi is the founder of Terapio, which makes the recombinant RLIP76 protein for treatment of radiation poisoning. However, Terapio does not work on the RLIP76-blockading technology that is the crux of the anticancer treatment strategy.

Explore further: Oncolytic viruses effectively target and kill pancreatic cancer stem cells

Related Stories

Oncolytic viruses effectively target and kill pancreatic cancer stem cells

May 9, 2011
Oncolytic viruses quickly infect and kill cancer stem cells, which may provide a treatment for tumors that are resistant to conventional chemotherapy and radiation, particularly pancreatic cancer, according to new research ...

Nerve growth factors elevated in pancreatic cancer model

June 19, 2012
Severe pain is a major symptom of pancreatic cancer. The results of a new study show that four different factors involved in the growth and maintenance of nerves are elevated in a mouse model of pancreatic cancer. This is ...

Studies show that pancreatic cancer can run but not always hide from the immune system

June 11, 2012
A pair of recent studies describes how pancreatic cancer cells produce a protein that attracts the body's immune cells and tricks them into helping cancer cells grow. The research, published by Cell Press in the June 12th ...

Gene identified in increasing pancreatic cancer risk

December 29, 2011
Mutations in the ATM gene may increase the hereditary risk for pancreatic cancer, according to data published in Cancer Discovery, the newest journal of the American Association for Cancer Research.

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.